# Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

> **NCT04329130** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 44 (estimated)

## Conditions studied

- Relapsed or Refractory Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Chidamide, Lenalidomide

## Key facts

- **NCT ID:** NCT04329130
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-27
- **Primary completion:** 2022-03-26
- **Final completion:** 2025-03-26
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04329130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04329130, "Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04329130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*